Back to today’s briefing

Story perspectives

Gilead's 2026 Forecast Misses Mark, Shares Drop 6%

2/11/2026

30 6 Full Breakdown

Summary

Gilead's Disappointing Forecast

Gilead Sciences, Inc. issued a 2026 forecast that fell short of analysts' expectations, leading to about a 6% drop in its shares.
The forecast projects 2026 drug sales of $29.6 to $30.0 billion, below the $30.2 billion consensus.
CEO Daniel O'Day projected Yeztugo sales of $800 million, below the $1 billion investor expectation.
Gilead posted strong fourth-quarter results, with Biktarvy sales rising 5% to $4 billion.

Summary

Gilead's Strong Sales

Gilead Sciences reported its Q4 and full-year 2025 results on February 10, 2026.
Q4 revenue was $7.93 billion, and 2025 product sales totaled $28.9 billion.
HIV sales were strong, with Biktarvy generating $4 billion.
Gilead expects a 10% decline in cell therapy sales due to competition.
For 2026, the company projects total product sales of $29.6–$30 billion, with Yeztugo at $800 million, although investors remain cautious due to potential declines.

1 of 2

Gilead's Disappointing Forecast

Gilead Sciences, Inc. issued a 2026 forecast that fell short of analysts' expectations, leading to about a 6% drop in its shares.
The forecast projects 2026 drug sales of $29.6 to $30.0 billion, below the $30.2 billion consensus.
CEO Daniel O'Day projected Yeztugo sales of $800 million, below the $1 billion investor expectation.
Gilead posted strong fourth-quarter results, with Biktarvy sales rising 5% to $4 billion.

1 / 2